Raxium, prepared in the form of enteric-coated tablets, with the active ingredient rabeprazole sodium, is commonly used in the prevention and treatment of gastric and duodenal ulcers, gastroesophageal reflux or problems related to increased gastric acid secretion.

Pylobact contains the main ingredients Omeprazole, Clarithromycin and Tinidazole, one box of Pylobact has 7 sets of drugs corresponding to a 7-day treatment regimen. This form facilitates patients to easily comply with the treatment regimen to eradicate H. pylori bacteria in gastric and duodenal ulcers.

Helicobacter pylori (H. pylori) is one of the factors involved in the pathogenesis of various gastrointestinal diseases and may play a potential role in some extraintestinal diseases. Eradication therapy can improve the manifestations of Henoch-Schonlein purpura (HSP) and reduce the recurrence of Henoch-Schonlein purpura. Therefore, the results suggest that appropriate methods for detecting H. pylori infection should be applied in children with Henoch-Schonlein purpura.

Recently, H. pylori infection or H. pylori gastritis has been observed to be associated with iron deficiency anemia (IDA), and eradication therapy has been reported to be effective in improving ferrintin levels or even curing iron deficiency anemia. A similar relationship between idiopathic thrombocytopenic purpura (ITP), a common hematological disease in children, and H. pylori infection has also been revealed through several clinical studies conducted by physicians.